✦ LIBER ✦

The Efficacy of a NOP1 Agonist (SCH486757) in Subacute Cough

✍ Scribed by Ashley Woodcock; Robbie L. McLeod; Jonathan Sadeh; Jaclyn A. Smith

Publisher: Springer
Year: 2009
Tongue: English
Weight: 224 KB
Volume: 188
Category: Article
ISSN: 0341-2040
DOI: 10.1007/s00408-009-9197-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Age-related expression of σ1 receptors a

✍ Vân-Ly Phan; Yoshiaki Miyamoto; Toshitaka Nabeshima; Tangui Maurice 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 458 KB

## Abstract The σ~1~ receptor is a unique intracellular receptor whose activation results in an efficient modulation of several neurotransmitter responses. Its role as a target for the rapid nongenomic effects of neuro(active)steroids and the age‐related diminutions in steroid levels suggested that

Efficacy and tolerability of entacapone

Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study

✍ G. Fénelon; S. Giménez-Roldán; J. L. Montastruc; F. Bermejo; F. Durif; I. Bourde 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 121 KB

Efficacy and safety of the novel α4β2neu

Efficacy and safety of the novel α4β2neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study

✍ George Apostol; Walid Abi-Saab; Christopher J. Kratochvil; Lenard A. Adler; Wein 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 321 KB

Efficacy and safety of the PPARγ partial

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

✍ Kim Henriksen; Inger Byrjalsen; Per Qvist; Henning Beck-Nielsen; Gitte Hansen; B 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract ## Background Treatment of patients with perioxisome proliferator‐activated receptor‐γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator‐activated receptor‐γ agonists has not been esta

The selective estrogen receptor α agonis

The selective estrogen receptor α agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: A phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine

✍ Ronald F. van Vollenhoven; Jos G. A. Houbiers; Frank Buttgereit; Joanna in 't Ho 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 1 views